Search

The race to capture consumers' attention has rapidly increased in the past years. Besides the importance of the channels, the elements composing an ad are as crucial as ever in promoting compelling messages relevant to the target group. Music is one of the mechanisms through which the interest of consumers can be aroused while enhancing the advertising message and giving it more nuance. There have been several attempts to understand advertising music better, but most of the works focus on individual dimensions. There is a need to understand advertising music choices more coherently and complexly. The present study aims to provide a comprehensive instrument of several items that help understand musical congruency within an ad. The paper provides a content analysis of 95 global musical ads for 2019-2022. The primary product/service categories are reviewed, and the dimensions used in the analysis present the essential aspects of musical congruency, underlining the importance of original music composed for the ads, the capacity to adapt to various music sources, and giving additional importance to elements such as pitch, dynamics, and tempo. The paper offers a bigger picture of the musical landscape in advertising and interweaves music knowledge and elements with advertising purposes. [ABSTRACT FROM AUTHOR]

We aimed to investigate immunohistochemical expression of the p53 tumor suppressor protein, and the B-cell lymphoma-2 (Bcl-2) apoptotic protein in colorectal adenocarcinoma patients with or without type 2 diabetes mellitus (T2DM). Tissue sections from 95 paraffin-embedded colorectal adenocarcinomas, originating from 52 T2DM and 43 non-diabetic patients, were immunostained for p53 [Ventana mouse monoclonal primary antibody (mAb) in vitro diagnostic (IVD) anti-p53, clone Bp53-11] and Bcl-2 (Ventana mAb IVD anti-Bcl-2, clone Bcl-2/124). Immunohistochemistry analysis did not find statistically significant differences between the two groups, but analysis on subgroups of patients in terms of presence or absence of obesity identified overexpression of p53 (>70% of cells) in the T2DM obese patients compared to non-diabetics. Overexpression of p53 was present in 80% of tumor cells coming from T2DM obese patients compared to 37.2% of tumor cells coming from non-diabetics obese and non-obese, and in 36.6% of tumor cells coming from non-diabetic non-obese patients (p=0.024). There was a single non-diabetic obese patient with p53 overexpression. Most cancer cells of T2DM obese patients presented more frequently p53 overexpression by comparison with cancer cells of the T2DM non-obese patients (80% vs 40.5%, p=0.028). Bcl-2/p53 co-expression was an infrequent event in T2DM patients' group. The results of this study suggest that patients with colorectal adenocarcinoma that associate T2DM and obesity exhibit higher p53 protein expression in malignant cells. In conclusion, our research highlights that obesity is a potential key factor in the relationship between T2DM and colorectal cancer.